Moreover, SNAT1 overexpression is associated with a poorer prognosis of patients with breast cancer [14], osteosarcoma [13], AML [19], and gastric cancer [18], hinting at SNAT1 as a potential drug target for cancer therapy. This evidence concerns the gene SLC38A1 and breast carcinoma.